Astellas’ 9-Month Sales Dip 1.6%, but in Positive Territory If Forex Impact Excluded
To read the full story
Related Article
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
- Bullish New Drugs Mitigated Vesicare/Tarceva Patent Cliff: Astellas CEO
November 1, 2019
- Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
- Astellas Secures Q1 Growth as Xtandi, Betanis Offset LOE Impact
July 31, 2019
- Astellas’ Net Profit Soars 35% on Xtandi, Betanis
April 26, 2019
BUSINESS
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Chugai to Build New Research Building to Strengthen Process Development
July 25, 2025
- Chugai Drops Five Early-Stage Programs to Refocus Pipeline
July 25, 2025
- Pfizer Japan Recalls Syphilis Drug over Particulate Contamination
July 25, 2025
- Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
July 25, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…